Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 3/20 | 0.75 |
| ▸ | PPARG | P37231 | 3/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9263972 | 0.93 | SOAT1 (0.69) | SOAT1PPARGPPARASOAT2 | |
| SCHEMBL10587594 | 0.93 | SOAT1 (0.69) | SOAT1PPARGPPARASOAT2 | |
| Cl-277082 SCHEMBL29427720 | 0.86 | SOAT1 (1.00) | SOAT1PPARGPPARAPPARDSOAT2 | |
| Cl-277082 SCHEMBL408973 | 0.86 | SOAT1 (1.00) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL9257327 | 0.82 | SOAT1 (0.86) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL10587602 | 0.82 | SOAT1 (0.86) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL9252473 | 0.81 | SOAT1 (0.74) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL9256286 | 0.81 | SOAT1 (0.74) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL1764301 | 0.80 | SOAT1 (0.85) | SOAT1PPARGPPARAPPARDSOAT2 | |
| SCHEMBL9254742 | 0.80 | SOAT1 (0.56) | SOAT1PPARGPPARASOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | TNNI3, TNNT2, FABP3 | SOAT1 1163/4885PPARG 677/4885PPARA 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.